Literature DB >> 16876524

Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization.

Joaquin Marticorena1, Francisco Gomez-Ulla, Maribel Fernandez, Belen Pazos, Maria Jose Rodriguez-Cid, Manuel Sanchez-Salorio.   

Abstract

PURPOSE: To evaluate visual acuity changes and safety of combined treatment with photodynamic therapy (PDT) and intravitreal triamcinolone acetonide (IVTA) in myopic eyes with choroidal neovascularization (CNV).
DESIGN: Prospective interventional case series.
METHODS: Twelve eyes of 12 patients with subfoveal myopic CNV were treated with PDT followed by IVTA within a week. Changes in visual acuity and possible complications related to the combined therapy were assessed in periodic visits.
RESULTS: After combined therapy, a significant increase in mean visual acuity was observed at one, three, and six months. A significant increase of mean intraocular pressure was observed after seven days, one month, and three months. Ten patients (83%) required topical antiglaucomatous therapy during follow-up.
CONCLUSIONS: The combination of PDT and IVTA may increase the possibility of improving or stabilizing visual acuity in patients with subfoveal myopic CNV, but further studies are needed to asses the effects of this treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16876524     DOI: 10.1016/j.ajo.2006.03.003

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Javier A Montero; Jose M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

2.  The use of systemic steroids and photodynamic treatment for choroidal neovascularisation in young patients.

Authors:  C J Flaxel
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

3.  Repeated pseudoendophthalmitis after combined photodynamic therapy and intravitreal triamcinolone.

Authors:  J Marticorena; F Gomez-Ulla; M R Romano; I Luna
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-05-10       Impact factor: 3.117

4.  Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.

Authors:  Jose M Ruiz-Moreno; Javier A Montero; Pedro Amat-Peral
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-14       Impact factor: 3.117

5.  Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?

Authors:  Bogomil Voykov; Faik Gelisken; Werner Inhoffen; Michael Voelker; Karl Ulrich Bartz-Schmidt; Focke Ziemssen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-01-29       Impact factor: 3.117

Review 6.  Recent trends in the management of maculopathy secondary to pathological myopia.

Authors:  D Mitry; H Zambarakji
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-13       Impact factor: 3.117

7.  Combination therapy for choroidal neovascularisation.

Authors:  Albert J Augustin; Indre Offermann
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

8.  A systematic review of clinical practice guidelines for myopic macular degeneration.

Authors:  Yanxian Chen; Xiaotong Han; Iris Gordon; Sare Safi; Gareth Lingham; Jennifer Evans; Jinying Li; Mingguang He; Stuart Keel
Journal:  J Glob Health       Date:  2022-03-26       Impact factor: 4.413

9.  Two years follow-up outcome of verteporfin therapy for subfoveal choroidal neovascularization in pathologic myopia in Indian eyes.

Authors:  Nazimul Hussain; Rohit Khanna; Taraprasad Das; Raja Narayanan; Oluleye Tunji Sunday; Azad Gaurav Bansal; Rajeev Reddy
Journal:  Indian J Ophthalmol       Date:  2008 Nov-Dec       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.